Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
Licitra L, Störkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, Vermorken JB, von Heydebreck A, Esser R, Celik I, Ciardiello F. Licitra L, et al. Among authors: hirsch fr. Eur J Cancer. 2013 Apr;49(6):1161-8. doi: 10.1016/j.ejca.2012.11.018. Epub 2012 Dec 19. Eur J Cancer. 2013. PMID: 23265711 Clinical Trial.
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M. Cappuzzo F, et al. Among authors: hirsch fr. J Thorac Oncol. 2007 May;2(5):423-9. doi: 10.1097/01.JTO.0000268676.79872.9b. J Thorac Oncol. 2007. PMID: 17473658 Free article.
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV, Speake G, Holloway B, Bunn PA Jr, Franklin WA. Hirsch FR, et al. Cancer. 2008 Mar 1;112(5):1114-21. doi: 10.1002/cncr.23282. Cancer. 2008. PMID: 18219661 Free PMC article. Clinical Trial.
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Stewart JS, et al. Among authors: hirsch fr. J Clin Oncol. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289630 Clinical Trial.
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R; European EGFR Workshop Group. Pirker R, et al. Among authors: hirsch fr. J Thorac Oncol. 2010 Oct;5(10):1706-13. doi: 10.1097/JTO.0b013e3181f1c8de. J Thorac Oncol. 2010. PMID: 20871269 Free article.
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Herbst RS, et al. Among authors: hirsch fr. J Clin Oncol. 2010 Nov 1;28(31):4747-54. doi: 10.1200/JCO.2009.27.9356. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921467 Free PMC article. Clinical Trial.
βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer.
Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WE, Wohlschlaeger J. Christoph DC, et al. Among authors: hirsch fr. Br J Cancer. 2012 Aug 21;107(5):823-30. doi: 10.1038/bjc.2012.324. Epub 2012 Jul 26. Br J Cancer. 2012. PMID: 22836512 Free PMC article.
Epidermal growth factor receptor inhibition in lung cancer: status 2012.
Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Hirsch FR, et al. J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff. J Thorac Oncol. 2013. PMID: 23370315 Free article. Review.
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Keysar SB, et al. Among authors: hirsch fr. Cancer Res. 2013 Jun 1;73(11):3381-92. doi: 10.1158/0008-5472.CAN-12-4047. Epub 2013 Apr 10. Cancer Res. 2013. PMID: 23576557 Free PMC article.
Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Gridelli C, et al. Among authors: hirsch fr. Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27. Clin Lung Cancer. 2014. PMID: 24486058 Review.
470 results